NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free CPRX Stock Alerts $14.73 -0.37 (-2.45%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$14.73▼$15.2350-Day Range$13.18▼$17.0152-Week Range$11.09▼$17.76Volume989,900 shsAverage Volume1.49 million shsMarket Capitalization$1.74 billionP/E Ratio24.15Dividend YieldN/APrice Target$26.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Catalyst Pharmaceuticals alerts: Email Address Catalyst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside76.7% Upside$26.43 Price TargetShort InterestBearish6.06% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment0.96Based on 3 Articles This WeekInsider TradingSelling Shares$803,000 Sold Last QuarterProj. Earnings Growth20.44%From $1.81 to $2.18 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.99 out of 5 starsMedical Sector5th out of 910 stocksPharmaceutical Preparations Industry3rd out of 426 stocks 4.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCatalyst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.06% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 3.77%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 2.8 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Catalyst Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows16 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 45% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $803,000.00 in company stock.Percentage Held by Insiders12.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 20.44% in the coming year, from $1.81 to $2.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 24.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 24.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 198.45.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 0.83. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Read More CPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPRX Stock News HeadlinesApril 11, 2024 | insidertrades.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director David S. Tierney Sells 25,000 SharesMarch 30, 2024 | insidertrades.comBrian Elsbernd Sells 25,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) StockApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 23, 2024 | barrons.comCatalyst Pharmaceuticals Inc.April 22, 2024 | globenewswire.comCatalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024April 8, 2024 | msn.comSingle Catalyst Paves the Way for Efficient Drug SynthesisApril 7, 2024 | cnn.comCatalyst Pharmaceuticals, Inc.April 6, 2024 | seekingalpha.comCatalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 5, 2024 | nasdaq.comFirst Week of May 17th Options Trading For Catalyst Pharmaceuticals (CPRX)March 28, 2024 | finance.yahoo.comInsider Sell: Chief Compliance/Legal Officer Brian Elsbernd Sells 25,000 Shares of Catalyst ...March 28, 2024 | globenewswire.comCatalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness DayMarch 27, 2024 | markets.businessinsider.comDecoding 7 Analyst Evaluations For Catalyst PharmaceuticalsMarch 27, 2024 | globenewswire.comCatalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy SymposiumMarch 27, 2024 | investorplace.com3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch ListMarch 22, 2024 | finance.yahoo.comInvestors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three yearsMarch 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 15, 2024 | finance.yahoo.comCPRX Apr 2024 12.500 callMarch 15, 2024 | finance.yahoo.comCPRX Apr 2024 17.500 putMarch 14, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)March 14, 2024 | finance.yahoo.comCPRX Apr 2024 20.000 putMarch 14, 2024 | finanznachrichten.deSanthera Pharmaceuticals Holding AG: Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United StatesMarch 14, 2024 | finance.yahoo.comSanthera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United StatesMarch 14, 2024 | globenewswire.comSanthera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United StatesMarch 13, 2024 | markets.businessinsider.comCatalyst Pharmaceutical Gains Following US Commercial Launch Of AgamreeMarch 13, 2024 | globenewswire.comCatalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)March 10, 2024 | investorplace.com3 Sexy Small-Cap Stocks to Add Sizzle to Your PortfolioSee More Headlines Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees167Year Founded2002Price Target and Rating Average Stock Price Target$26.43 High Stock Price Target$34.00 Low Stock Price Target$23.00 Potential Upside/Downside+73.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.61 Trailing P/E Ratio24.93 Forward P/E Ratio8.40 P/E Growth0.83Net Income$71.41 million Net Margins17.93% Pretax Margin23.73% Return on Equity26.56% Return on Assets22.13% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.68 Sales & Book Value Annual Sales$398.20 million Price / Sales4.51 Cash Flow$2.07 per share Price / Cash Flow7.36 Book Value$3.30 per share Price / Book4.61Miscellaneous Outstanding Shares118,010,000Free Float103,732,000Market Cap$1.79 billion OptionableOptionable Beta0.89 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Patrick J. McEnany (Age 77)Co-Founder & Chairman Comp: $1.2MMr. Richard John Daly M.B.A. (Age 63)President, CEO & Director Comp: $63.12kDr. Steven R. Miller Ph.D. (Age 62)Executive VP, COO & Chief Scientific Officer Comp: $809.03kDr. Gary Ingenito M.D. (Age 68)Ph.D., Chief Medical & Regulatory Officer Comp: $751.85kMr. Jeffrey Del Carmen (Age 53)Executive VP & Chief Commercial Officer Comp: $711.7kMr. Michael W. Kalb CPA (Age 53)Executive VP & CFO Ms. Mary ColemanVP & Head of Investor RelationsMr. Brian Elsbernd J.D. (Age 60)Chief Compliance Officer & Chief Legal Officer Comp: $311.42kMr. Pete Curry Sr.Vice President of SalesDr. Stanley Iyadurai M.D.Ph.D., Senior Vice President of Medical Affairs & Drug DiscoveryMore ExecutivesKey CompetitorsSyndax PharmaceuticalsNASDAQ:SNDXSchrödingerNASDAQ:SDGRStructure TherapeuticsNASDAQ:GPCRAvidity BiosciencesNASDAQ:RNANewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInsiders & InstitutionsRaymond James Financial Services Advisors Inc.Sold 3,611 shares on 4/23/2024Ownership: 0.218%Paradiem LLCSold 16,924 shares on 4/23/2024Ownership: 0.154%Maryland State Retirement & Pension SystemBought 3,840 shares on 4/20/2024Ownership: 0.034%State of Alaska Department of RevenueBought 6,386 shares on 4/19/2024Ownership: 0.058%Sumitomo Mitsui Trust Holdings Inc.Bought 26,700 shares on 4/19/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions CPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price target for 2024? 5 equities research analysts have issued 12 month price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $23.00 to $34.00. On average, they expect the company's share price to reach $26.43 in the next twelve months. This suggests a possible upside of 76.7% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts. How have CPRX shares performed in 2024? Catalyst Pharmaceuticals' stock was trading at $16.81 at the start of the year. Since then, CPRX shares have decreased by 11.0% and is now trading at $14.96. View the best growth stocks for 2024 here. When is Catalyst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CPRX earnings forecast. How can I listen to Catalyst Pharmaceuticals' earnings call? Catalyst Pharmaceuticals will be holding an earnings conference call on Thursday, May 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.04. The biopharmaceutical company had revenue of $110.57 million for the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 26.56% and a net margin of 17.93%. What ETFs hold Catalyst Pharmaceuticals' stock? ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), ERShares NextGen Entrepreneurs ETF (ERSX), First Trust Active Factor Small Cap ETF (AFSM) and Hartford Multifactor Small Cap ETF (ROSC). What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $455.0 million-$475.0 million, compared to the consensus revenue estimate of $463.2 million. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Raymond James Financial Services Advisors Inc. (0.22%), Paradiem LLC (0.15%), Allspring Global Investments Holdings LLC (0.12%), Juncture Wealth Strategies LLC (0.08%), Los Angeles Capital Management LLC (0.07%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CPRX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
